Future prostate cancer screening among middle-aged men (ie, aged 55-60 years) should be individually tailored based on baseline PSA levels to reduce the risk of overdiagnosis and overtreatment of indolent cancers. The gene discussed is KLK3; the disease is prostate carcinoma.